It is well known that total cholesterol is not a good predictor of mortality and cardiovascular events and that LDL-cholesterol, non-HDL cholesterol and ratios perform better. Hence, the authors may need to highlight in which way their manuscript will provide novelty. Moreover, the methodology of the biomarker evaluation may need some clarification.
1. The authors should explain in the introduction why the three criteria mentioned above are used for evaluation. 2. A more precise description what is meant by the "signal to noise" ratio could be helpful for the reader. 3. It seems quite difficult to disentangle signal and noise since there are so many factors affecting lipid levels that are not considered (e.g. diet, physical activity, inflammation….). 4. The prognostic information (association with end-points) of the change in a parameter after statin treatment may represent another important criterion. 5. At least in many European countries rather the crude values (e.g. total cholesterol, LDL cholesterol, HDL cholesterol…) than the ratios are used for the initial risk assessment. 6. The terminology apolipoprotein A is not correct (apolipoprotein A1?).
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GENERAL COMMENTS
This is a well written manuscript on an important topic and the substudy has been thoughtfully conducted, although largely confirmatory of other work. The limitations are well acknowledged. I have just a few minor comments: Abstract: does not state the cardiovascular outcome measure. Results: I think it would be useful to state the number of CV events in each group at the start. There is some repetition of methods in lines 33-38 page 9. Did you consider any form of statistical testing regarding the differences in hazard ratios between the different lipid measures?
VERSION 1 -AUTHOR RESPONSE
Reviewer: Guenther Silbernagel, University of Bern, Dr. Glasziou et al performed a substudy in the well renowned LIPID cohort evaluating different lipid measurements with regard to their clinical utility. They generated a score comprising three criteria: 1) clinical validity 2) responsiveness to therapy changes 3) the size of the long-term "signal-to-noise" ratio. Based on the score the authors suggest that non-HDL cholesterol and ratios among cholesterol subfractions are superior for guiding lipid lowering treatment compared with individual measurements.
1. The authors should explain in the introduction why the three criteria mentioned above are used for evaluation.
RESPONSE/CHANGES: We now reference our recently published article in the Journal of Clinical Epidemiology (JCE) which spells out the justification for the three criteria in detail (reference 10).
2. A more precise description what is meant by the "signal to noise" ratio could be helpful for the reader.
RESPONSE/CHANGES:
We have provided additional explanation in both Introduction and Methods, and now also refer to the JCE paper (new reference 10) for further details.
3. It seems quite difficult to disentangle signal and noise since there are so many factors affecting lipid levels that are not considered (e.g. diet, physical activity, inflammation….).
RESPONSE/CHANGE: If short-term these others factors are part of the "noise". We have tried to clarify this relationship in the text (Methods, paragraph 4, new first sentence).
4. The prognostic information (association with end-points) of the change in a parameter after statin treatment may represent another important criterion.
RESPONSE/CHANGE: We agree, and had considered this option in planning. The current analysis is only on baseline levels, but we did not have data on change for some parameters. We now point this out in the limitations paragraph of the Discussion.
5. At least in many European countries rather the crude values (e.g. total cholesterol, LDL cholesterol, HDL cholesterol…) than the ratios are used for the initial risk assessment.
